PAH News

April 16, 2021April 16, 2021

Fungus Used in Chinese Medicine Eased PAH Damage in Rat Model

News, PAH News

Treatment with a fungus called Ophiocordyceps sinensis eased disease signs and improved survival in a rat model of pulmonary arterial hypertension (PAH), suggesting a potential to treat patients. The findings ... Read more

April 12, 2021April 14, 2021

Uptravi Can Help PAH Patients at Moderate, High Risk of Death, Registry Data Show

News, PAH News

More than three-quarters (76%) of adults with pulmonary arterial hypertension (PAH) being treated with Uptravi (selexipag) either saw no increase or a decline in their risk of death over one ... Read more

April 7, 2021April 7, 2021

Phase 2 Trial Updates on Sotatercept in Treating PAH Set for ATS 2021

News, PAH News

Treatment with Acceleron Pharma’s sotatercept appears to be effective and generally well tolerated in people with pulmonary arterial hypertension (PAH), according to new data from the ongoing PULSAR and SPECTRA ... Read more

April 5, 2021April 6, 2021

Antiparasitic Shows Potential as PAH Treatment in Preclinical Study

News, PAH News

Diminazene aceturate (DIZE), an approved antiparasitic medication, lessened the development of pulmonary arterial hypertension (PAH) in a rat model, a study has demonstrated. These findings support further investigation of DIZE ... Read more

March 31, 2021March 31, 2021

Some PAH Patients May Benefit from Switch to Adempas

News, PAH News

Intermediate-risk pulmonary arterial hypertension (PAH) patients may see their symptoms improve after switching from phosphodiesterase-5 inhibitors (PDE-5i) to Adempas (riociguat), results from the Phase 4 REPLACE clinical trial show. The transition ... Read more

March 24, 2021March 24, 2021

PulmoSIM Therapeutics Opens With Focus on Better Treating PAH

News, PAH News

VeriSIM Life has opened PulmoSIM Therapeutics, its pharmaceutical subsidiary focused on developing treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), before moving to other rare respiratory diseases. “We ... Read more

March 10, 2021March 10, 2021

Uptravi Safe and Effective in Temporary Use as IV Infusion, PAH Trial Finds

News, PAH News

Intravenous use of Uptravi (selexipag) is safe and well-tolerated by pulmonary arterial hypertension (PAH) patients temporarily unable to take this therapy as an oral tablet, a trial found. Patients reported mild side ... Read more

February 24, 2021February 24, 2021

Insmed Announces Top-line Results from Phase 1 Trial of TPIP

News, PAH News

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by ... Read more

February 22, 2021February 22, 2021

FDA Approves Alembic’s Generic Injection of Remodulin for PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has approved Alembic Pharmaceuticals’ injectable formulation of treprostinil, a generic version of Remodulin, to treat patients with pulmonary arterial hypertension (PAH), the company ... Read more

February 19, 2021February 19, 2021

Remunity Pump on Market for Dispensing Remodulin

News, PAH News

Remunity, an innovative pump for Remodulin (treprostinil) to treat adults with pulmonary arterial hypertension (PAH), has launched commercial sales, according to the device’s developer, United Therapeutics. The Remunity system allows ... Read more